Vivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Vivo Capital LLC increased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 116.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,487,903 shares of the company’s stock after buying an additional 1,875,000 shares during the period. Trevi Therapeutics accounts for 1.6% of Vivo Capital LLC’s holdings, making the stock its 12th biggest position. Vivo Capital LLC owned about 4.54% of Trevi Therapeutics worth $14,370,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Trevi Therapeutics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 1,299,322 shares of the company’s stock worth $5,354,000 after buying an additional 35,156 shares during the period. Rosalind Advisors Inc. lifted its holdings in Trevi Therapeutics by 41.7% during the fourth quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company’s stock valued at $4,378,000 after purchasing an additional 312,500 shares in the last quarter. State Street Corp grew its position in shares of Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after purchasing an additional 53,051 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Trevi Therapeutics by 120.5% during the fourth quarter. JPMorgan Chase & Co. now owns 221,664 shares of the company’s stock worth $913,000 after purchasing an additional 121,147 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Trevi Therapeutics by 14.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company’s stock worth $713,000 after purchasing an additional 22,145 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Insider Buying and Selling

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 24.37% of the company’s stock.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $6.07 on Monday. The firm’s 50-day moving average is $5.50 and its two-hundred day moving average is $4.18. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39. The company has a market capitalization of $586.86 million, a PE ratio of -13.80 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Sell-side analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Wall Street Analyst Weigh In

TRVI has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, April 8th. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $9.00 to $29.00 in a research note on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Oppenheimer raised their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $17.56.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.